EUDA Highlights Shenzhen Inno’s Approval Under Shenzhen Key Industry R&D Program for TCR-T Cell Therapy Development
· euda health holdings ltd
AI Briefing
- EUDA Health Holdings Limited's subcompany Shenzhen Inno Immune Co., Ltd. receives approval under 2025 Shenzhen Key Industry R&D Program for TCR-T cell therapy development.
- The approval was granted by the Shenzhen government.
- EUDA Health Holdings Limited will benefit from the support of the Shenzhen government for its TCR-T cell therapy development.
Advertisement